Campbell & CO Investment Adviser LLC Has $710,000 Stake in Veeva Systems Inc. $VEEV

Campbell & CO Investment Adviser LLC reduced its stake in Veeva Systems Inc. (NYSE:VEEV) by 80.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,383 shares of the technology company’s stock after selling 10,052 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Veeva Systems were worth $710,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in VEEV. Vanguard Group Inc. boosted its position in Veeva Systems by 1.4% in the second quarter. Vanguard Group Inc. now owns 14,971,425 shares of the technology company’s stock valued at $4,311,471,000 after buying an additional 210,859 shares in the last quarter. Alliancebernstein L.P. lifted its stake in shares of Veeva Systems by 3.7% in the 2nd quarter. Alliancebernstein L.P. now owns 5,705,648 shares of the technology company’s stock valued at $1,643,113,000 after acquiring an additional 205,997 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Veeva Systems by 2.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,316,274 shares of the technology company’s stock valued at $955,030,000 after acquiring an additional 85,516 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Veeva Systems by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 3,092,539 shares of the technology company’s stock valued at $888,108,000 after acquiring an additional 114,003 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in Veeva Systems by 111.7% during the 2nd quarter. AQR Capital Management LLC now owns 1,838,046 shares of the technology company’s stock worth $526,508,000 after acquiring an additional 969,905 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Thomas D. Schwenger sold 1,000 shares of Veeva Systems stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total value of $231,430.00. Following the completion of the transaction, the insider directly owned 23,204 shares of the company’s stock, valued at approximately $5,370,101.72. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 10.30% of the company’s stock.

Analysts Set New Price Targets

VEEV has been the subject of several research reports. Truist Financial upgraded Veeva Systems from a “hold” rating to a “buy” rating in a research report on Thursday, January 8th. KeyCorp reaffirmed a “sector weight” rating on shares of Veeva Systems in a research note on Friday, December 12th. TD Cowen upgraded shares of Veeva Systems from a “hold” rating to a “buy” rating and lifted their target price for the stock from $297.00 to $380.00 in a research report on Tuesday, October 7th. Wells Fargo & Company reduced their target price on shares of Veeva Systems from $341.00 to $333.00 and set an “overweight” rating on the stock in a report on Tuesday, November 25th. Finally, Wall Street Zen cut shares of Veeva Systems from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Eighteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $308.04.

Veeva Systems Price Performance

Shares of VEEV stock opened at $216.00 on Wednesday. The stock has a market capitalization of $35.51 billion, a PE ratio of 42.02, a PEG ratio of 1.64 and a beta of 1.07. The business’s 50 day simple moving average is $236.89 and its 200 day simple moving average is $268.07. Veeva Systems Inc. has a one year low of $201.54 and a one year high of $310.50.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings results on Thursday, November 20th. The technology company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.95 by $0.09. Veeva Systems had a net margin of 27.93% and a return on equity of 13.68%. The firm had revenue of $0.81 million during the quarter, compared to analyst estimates of $792.37 million. During the same quarter last year, the business earned $1.75 EPS. The company’s revenue was up 16.0% compared to the same quarter last year. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. As a group, research analysts expect that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Veeva Systems announced that its board has approved a stock repurchase program on Monday, January 5th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the technology company to reacquire up to 5.5% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.